Hong Kong) A research report on August 6 stated that the normalization of medical insurance negotiations will continue to benefit innovative drugs. Considering that the current medical insurance capacity is relatively high for small indications of innovative drugs such as PD-1, China Merchants Securities judges that the price risk of innovative drug medical insurance negotiations in the short term will be reduced accordingly, which will continue to benefit leading innovative drug companies to maintain their leading market status. China Merchants Securities continued to first promote WuXi AppTec, Cinda Biotech, and Arctic China.
On August 13th, the Hong Kong stock market closed, WuXi AppTec rose 0.62% to 113.3 Hong Kong dollars; A shares closed, WuXi AppTec fell 1.85% to 107.13 yuan.